Published in Cancer Weekly, April 26th, 2005
In parallel with this activity, Metabasis and Sankyo, together and separately, are evaluating what, if any, next steps should be taken in the CS-917 program.
"While the recent findings in the CS-917 development program are unfortunate and the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.